Chronic lower back pain (LBP) is the leading cause of disability and morbidity worldwide. More than 700 million people globally of all ages are affected each year. LBP is a major cause of reduced activity and work absence, and imposes an economic burden of nearly ~€240 billion every year in the EU. iPSpine aims to investigate and develop a new therapy for LBP using induced pluripotent stem cells (iPSCs). The project will develop an advanced therapy using iPS-technology and smart biomaterials that will be translated from laboratory models into a clinically relevant animal model. By the end of the project, the therapy should be ready for advancement to the first human clinical trial.
A full list of iPSpine publications is available on Zenodo.
Click the icon to view.